Evidence map›Paper›PMID 26683340›Full record

ArticleMolecular cancer2015

Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma.

Bo Kong, Tao Cheng, Chengjia Qian, Weiwei Wu, Katja Steiger, Jing Cao, Anna Melissa Schlitter, Ivonne Regel, Susanne Raulefs, Helmut Friess and 4 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Bo KongDepartment of Surgery, Technische Universität München (TUM), Munich, Germany.
Tao ChengDepartment of Surgery, Technische Universität München (TUM), Munich, Germany.
Chengjia QianDepartment of Surgery, Technische Universität München (TUM), Munich, Germany.
Weiwei WuDepartment of Surgery, Technische Universität München (TUM), Munich, Germany.
Katja SteigerInstitute of Pathology, TUM, Munich, Germany.
Jing CaoDepartment of Surgery, Technische Universität München (TUM), Munich, Germany.
Anna Melissa SchlitterInstitute of Pathology, TUM, Munich, Germany.
Ivonne RegelDepartment of Surgery, Technische Universität München (TUM), Munich, Germany.
Susanne RaulefsDepartment of Surgery, Technische Universität München (TUM), Munich, Germany.
Helmut FriessDepartment of Surgery, Technische Universität München (TUM), Munich, Germany.
Mert ErkanDepartment of Surgery, Technische Universität München (TUM), Munich, Germany.
Irene EspositoInstitute of Pathology, TUM, Munich, Germany.
Jörg KleeffDepartment of Surgery, Technische Universität München (TUM), Munich, Germany.
Christoph W MichalskiDepartment of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany. cwmichalski@gmail.com.
Technical University of Munich · DEHeidelberg University · DEHeinrich Heine University Düsseldorf · DERoyal Liverpool and Broadgreen University Hospital NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic acinar cell carcinoma (ACC) is a rare tumor entity with an unfavorable prognosis. Recent whole-exome sequencing identified p53 mutations in a subset of human ACC. Activation of the mammalian target of rapamycin (mTOR) pathway is associated with various pancreatic neoplasms. We thus aimed at analyzing whether activation of mTOR with a concomitant loss of p53 may initiate ACC.

methodsWe generated transgenic mouse models in which mTOR was hyperactivated through pancreas-specific, homozygous tuberous sclerosis 1 (Tsc1) deficiency, with or without deletion of p53 (Tsc1 (-/-) and Tsc1 (-/-) ; p53 (-/-) ). Activity of mTOR signaling was investigated using mouse tissues and isolated murine cell lines. Human ACC specimens were used to corroborate the findings from the transgenic mouse models.

resultsHyperactive mTOR signaling in Tsc1 (-/-) mice was not oncogenic but rather induced a near-complete loss of the pancreatic acinar compartment. Acinar cells were lost as a result of apoptosis which was associated with p53 activation. Concomitantly, ductal cells were enriched. Ablation of p53 in Tsc1-deficient mice prevented acinar cell death but promoted formation of acinar cells with severe nuclear abnormalities. One out of seven Tsc1 (-/-) ; p53 (-/-) animals developed pancreatic tumors showing a distinctive tumor morphology, reminiscent of human ACC. Hyperactive mTOR signaling was also detected in a subset of human ACC.

conclusionHyperactive mTOR signaling combined with loss of p53 in mice induces tumors similar to human ACC.

Indexed as

AnimalsApoptosisCarcinoma, Acinar CellHumansMice, Inbred BALB CMice, Inbred C57BLMice, NudeMice, TransgenicNeoplasm TransplantationOrgan SpecificityPancreasPancreatic NeoplasmsSignal TransductionTOR Serine-Threonine KinasesTuberous Sclerosis Complex 1 ProteinTumor Suppressor Protein p53mTOR protein, mouseTOR Serine-Threonine KinasesTSC1 protein, humanTsc1 protein, mouseTuberous Sclerosis Complex 1 ProteinTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID26683340
PMCPMC4683950
OpenAlexW2197563344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.